BioSpectrum the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

GenWorks introduces FenomPro breath analyser for testing asthma

24 May 2023 | News

A simple tool for the diagnosis, screening & monitoring of asthma patients



Bengaluru-based GenWorks, an initiative by GE, has announced the launch of its product called FenomPro which is a breath analyser used for testing the FeNO levels of patients to help more and more patients know if they are suffering from asthma.

The FenomPro ensures efficient testing of FeNO as it is a simple tool for the diagnosis, screening, and monitoring of asthma. The FenomPro is used for simple clinical applications and it comes with a rechargeable battery for easy portability.

It has a user-friendly interface and gives the test results in just 28 seconds. The FeNO test is accurate for understanding if the patients require treatment and prescription of inhalers or not.

FeNO stands for Fractional Exhaled Nitric Oxide. It is a test done to mark the airway inflammation eosinophil which is a blood cell that gets increased in allergic inflammation such as allergic asthma. Eosinophils release a certain chemical known as nitric oxide which can be measured in the patient's breath by a test called FeNO. This test can be done in people suggestive of asthma. If the FeNO value is elevated, it indicates that the patient will show an excellent response to a special group of medicines called inhaled corticosteroids.

According to Dr SK Chhabra, a leading pulmonologist, "FeNO is excellent for differentiating if a person has normal airways or inflamed airways. The cut off between a normal person and an asthmatic is 25-50. Above 50 is surely asthmatic and less than 25 may be a normal person or an asthmatic patient who has been adequately treated. FeNO also helps in deciding if the person will respond to some medicines and comply with a treatment which is helpful in figuring out the correct action plan."